Cargando...
Concomitant (177)Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
BACKGROUND: The role of concomitant peptide receptor radionuclide therapy (PRRT) and capecitabine therapy has shown benefit in gastroenteropancreatic neuroendocrine tumors. However, data reporting its role in paraganglioma (PGL) patients is lacking. The aim of this study was to evaluate the role of...
Gardado en:
| Publicado en: | EJNMMI Res |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer Berlin Heidelberg
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6365580/ https://ncbi.nlm.nih.gov/pubmed/30725219 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13550-019-0484-y |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|